Skip to content
Search

Latest Stories

Pharmacists’ support doubles smoking cessation success

New research commissioned by J&J finds interest in quitting has increased during the pandemic...

Community pharmacists’ role has more than doubled smoking cessation success rate during the Covid-19 pandemic, when compared with either no support or lower intensity support, a latest study has revealed.


More than half (55 per cent) of smokers say they want to be both tobacco and nicotine free and four in ten (43 per cent) are looking to pharmacists to provide the advice they need on smoking cessation, according to a new research commissioned by pharma giant Johnson & Johnson.

Consumer interest in smoking cessation is also on the rise - with 28 per cent of UK smokers citing Covid-19 as the main reason for quitting.

Over eight out of ten pharmacists who participated in the J&J survey have stated that they are interested in the management and treatment of smokers looking to quit.

The consumer interest in smoking cessation is on the rise, with 28 per cent of UK smokers citing Covid-19 as the main reason for quitting, the study pointed out.

Dr Mark Watt MD, medical affairs senior director, Johnson & Johnson Consumer Health EMEA said: “We know that community pharmacy-delivered behavioural intervention and support, together with pharmacotherapeutic advice, is invaluable for smokers wishing to quit. With more and more smokers trying to quit, pharmacists have a vital role to play”.

Pharmacists surveyed by J&J show that they see a clear role for themselves as a partner to smokers, specifically:

  • discussing the benefits of quitting smoking
  • recommending behavioural intervention in response to key life events such as pregnancy or illness, and calendar events such as a New Year Resolution to give up smoking or no smoking days
  • explaining and discussing smoking cessation medications such as NRT

Top tips for pharmacists to support smokers wishing to quit include:

  • assess the patient’s overall lung health (carbon monoxide testing and COPD check)
  • provide lifestyle advice including withdrawal symptom management
  • identify best treatment for individual patient
  • provide patient with access to smoking cessation services including helplines

Meanwhile, pharmacists most commonly recommend either one or two concurrent Nicotine Replacement Therapies (NRT) with an average of 88 per cent recommending at least one format of NRT, while 97 per cent believe smokers are more likely to quit for good by using a combination of two or more NRT products.

Around 94 per cent of pharmacists say they are most likely to recommend patches and a third (34 per cent) say they are most likely to recommend gum (34 per cent).

However, study shows that patients are more likely to quit for good by using two NRT products in combination, compared to using just one NRT product alone.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less